E
VRCA icon

Ergoteles’s Verrica Pharmaceuticals VRCA Stock Holding History

Ergoteles’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,555
Closed -$97.8K – 1784
2022
Q4 		$97.8K Buy
+3,555
New +$94.9K ﹤0.01% 1226
2022
Q3 		– Sell
-6,430
Closed -$123K – 2017
2022
Q2 		$123K Buy
+6,430
New +$323K ﹤0.01% 1464

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ergoteles's VRCA Position: Q1 2023 in Review

Ergoteles sold out of Verrica Pharmaceuticals (VRCA) in Q1 2023, closing a stake of 3,555 shares — an estimated $97.8K sold.

Ergoteles first reported a position in VRCA in Q2 2022 and held it in 2 quarters. The position peaked at $123K in Q2 2022. 59 funds tracked by Wall St. Rank hold VRCA as of Q1 2023.

  • Ergoteles reported no remaining Verrica Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 3,555 Verrica Pharmaceuticals shares in Q1 2023, an estimated $97.8K.
  • Ergoteles first reported a position in Verrica Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Verrica Pharmaceuticals position peaked at $123K in Q2 2022.
  • 59 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.